These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21474565)

  • 41. Post-renal transplantation hypophosphatemia: a review and novel insights.
    Ghanekar H; Welch BJ; Moe OW; Sakhaee K
    Curr Opin Nephrol Hypertens; 2006 Mar; 15(2):97-104. PubMed ID: 16481873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe?
    Larsson TE
    Nephrol Dial Transplant; 2010 May; 25(5):1376-81. PubMed ID: 20124546
    [No Abstract]   [Full Text] [Related]  

  • 43. Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study.
    Kawarazaki H; Shibagaki Y; Fukumoto S; Kido R; Ando K; Nakajima I; Fuchinoue S; Fujita T; Fukagawa M; Teraoka S
    Ther Apher Dial; 2011 Oct; 15(5):481-7. PubMed ID: 21974702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic kidney disease--mineral and bone disorder: a complex scenario.
    Mejía N; Roman-García P; Miar AB; Tavira B; Cannata-Andía JB
    Nefrologia; 2011; 31(5):514-9. PubMed ID: 21959717
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation.
    Sari V; Atiqi R; Hoorn EJ; Heijboer AC; van Gelder T; Hesselink DA
    Neth J Med; 2017 Mar; 75(2):65-73. PubMed ID: 28276325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FGF23: fashion or physiology?
    Wolf M
    Clin J Am Soc Nephrol; 2010 Oct; 5(10):1727-9. PubMed ID: 20847097
    [No Abstract]   [Full Text] [Related]  

  • 47. FGF23: a key player in mineral and bone disorder in CKD.
    Komaba H; Fukagawa M
    Nefrologia; 2009; 29(5):392-6. PubMed ID: 19820750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease.
    Galitzer H; Ben-Dov IZ; Silver J; Naveh-Many T
    Kidney Int; 2010 Feb; 77(3):211-8. PubMed ID: 20016468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Soluble Klotho and intact fibroblast growth factor 23 in long-term kidney transplant patients.
    Bleskestad IH; Thorsen IS; Jonsson G; Skadberg Ø; Bergrem H; Gøransson LG
    Eur J Endocrinol; 2015 Apr; 172(4):343-50. PubMed ID: 25572388
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oxidative stress and renal interstitial fibrosis in patients after renal transplantation: current state of knowledge.
    Kędzierska K; Domański M; Sporniak-Tutak K; Dołęgowska B; Ciechanowski K
    Transplant Proc; 2011 Dec; 43(10):3577-83. PubMed ID: 22172808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
    Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
    Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients.
    Eisenga MF; van Londen M; Leaf DE; Nolte IM; Navis G; Bakker SJL; de Borst MH; Gaillard CAJM
    J Am Soc Nephrol; 2017 Dec; 28(12):3639-3646. PubMed ID: 28774998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury.
    Cassis P; Gallon L; Benigni A; Mister M; Pezzotta A; Solini S; Gagliardini E; Cugini D; Abbate M; Aiello S; Rocchetta F; Scudeletti P; Perico N; Noris M; Remuzzi G
    Kidney Int; 2012 May; 81(9):903-18. PubMed ID: 22318420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Fibroblast growth factor-23 (FGF-23). Part III. Relationship between FGF-23 serum concentration and cardio-vascular morbidity and mortality].
    Fedak D; Bigaj K; Sułowicz W
    Przegl Lek; 2011; 68(9):614-8. PubMed ID: 22335012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PTH, FGF-23 and early CKD.
    Rodriguez M; Felsenfeld AJ
    Nephrol Dial Transplant; 2008 Nov; 23(11):3391-3. PubMed ID: 18676347
    [No Abstract]   [Full Text] [Related]  

  • 56. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.
    Seiler S; Reichart B; Roth D; Seibert E; Fliser D; Heine GH
    Nephrol Dial Transplant; 2010 Dec; 25(12):3983-9. PubMed ID: 20525642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fish and omega-3 fatty acid intake in relation to circulating fibroblast growth factor 23 levels in renal transplant recipients.
    Baia LC; Van den Berg E; Vervloet MG; Heilberg IP; Navis G; Bakker SJ; Geleijnse JM; Kromhout D; Soedamah-Muthu SS; De Borst MH;
    Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1310-6. PubMed ID: 25063539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after renal transplantation.
    Yilmaz MI; Sonmez A; Saglam M; Yaman H; Kilic S; Turker T; Unal HU; Gok M; Cetinkaya H; Eyileten T; Oguz Y; Caglar K; Vural A; Mallamaci F; Zoccali C
    Am J Nephrol; 2013; 37(2):126-34. PubMed ID: 23391995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Fibroblast growth factor 23 (FGF 23): a new fosfaturic hormone?].
    Negri AL
    Nefrologia; 2003; 23(6):478-81. PubMed ID: 15002780
    [No Abstract]   [Full Text] [Related]  

  • 60. Are fibroblast growth factor 23 concentrations in renal transplant patients different from non-transplanted chronic kidney disease patients?
    Filler G; Liu D; Sharma AP; Grimmer J
    Pediatr Transplant; 2012 Feb; 16(1):73-7. PubMed ID: 22121948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.